Healthcare provider profile · identity verified

Phillip Kadaj, MD

Internal Medicine · MIDLAND, MI · NPI 1417157165

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	803	196
Levothyroxine Sodium	Levothyroxine Sodium	573	139
Amlodipine Besylate	Amlodipine Besylate	411	109
Lisinopril	Lisinopril	360	98
Losartan Potassium	Losartan Potassium	346	88
Omeprazole	Omeprazole	322	80
Tamsulosin Hcl	Tamsulosin Hcl	234	64
Gabapentin	Gabapentin	227	42
Allopurinol	Allopurinol	212	48
Mounjaro	Tirzepatide	209	33
Rosuvastatin Calcium	Rosuvastatin Calcium	197	54
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	193	36
Metformin Hcl	Metformin Hcl	187	51
Pantoprazole Sodium	Pantoprazole Sodium	186	49
Potassium Chloride	Potassium Chloride	165	42
Tramadol Hcl	Tramadol Hcl	161	26
Metoprolol Succinate	Metoprolol Succinate	160	44
Simvastatin	Simvastatin	159	47
Ozempic	Semaglutide	158	35
Hydrochlorothiazide	Hydrochlorothiazide	151	45
Furosemide	Furosemide	148	40
Pravastatin Sodium	Pravastatin Sodium	147	38
Sertraline Hcl	Sertraline Hcl	133	39
Eliquis	Apixaban	126	32
Glipizide Er	Glipizide	123	29
Finasteride	Finasteride	111	30
Trazodone Hcl	Trazodone Hcl	96	24
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	95	26
Metformin Hcl Er	Metformin Hcl	95	33
Fluticasone Propionate	Fluticasone Propionate	94	26
Buspirone Hcl	Buspirone Hcl	91	25
Carvedilol	Carvedilol	89	24
Montelukast Sodium	Montelukast Sodium	89	19
Bisoprolol Fumarate	Bisoprolol Fumarate	86	23
Xarelto	Rivaroxaban	74	12
Alendronate Sodium	Alendronate Sodium	73	19
Celecoxib	Celecoxib	73	18
Duloxetine Hcl	Duloxetine Hcl	73	17
Trulicity	Dulaglutide	70	17
Albuterol Sulfate Hfa	Albuterol Sulfate	69	26
Ropinirole Hcl	Ropinirole Hcl	69	13
Chlorthalidone	Chlorthalidone	68	18
Donepezil Hcl	Donepezil Hcl	67	21
Olmesartan Medoxomil	Olmesartan Medoxomil	66	21
Famotidine	Famotidine	62	12
Citalopram Hbr	Citalopram Hydrobromide	61	17
Prednisone	Prednisone	60	35
Tizanidine Hcl	Tizanidine Hcl	60	17
Clopidogrel	Clopidogrel Bisulfate	59	16
Metoprolol Tartrate	Metoprolol Tartrate	59	16
Alprazolam	Alprazolam	58	21
Lorazepam	Lorazepam	57	11
Fluoxetine Hcl	Fluoxetine Hcl	55	13
Venlafaxine Hcl Er	Venlafaxine Hcl	53	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	47	16
Paroxetine Hcl	Paroxetine Hcl	45	suppressed
Ramipril	Ramipril	45	12
Warfarin Sodium	Warfarin Sodium	44	12
Escitalopram Oxalate	Escitalopram Oxalate	43	14
Atenolol	Atenolol	42	13
Myrbetriq	Mirabegron	41	11
Farxiga	Dapagliflozin Propanediol	39	suppressed
Clonazepam	Clonazepam	38	suppressed
Diazepam	Diazepam	37	11
Glipizide	Glipizide	37	12
Synthroid	Levothyroxine Sodium	36	13
Bupropion Xl	Bupropion Hcl	35	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	34	suppressed
Mirtazapine	Mirtazapine	33	suppressed
Jardiance	Empagliflozin	31	11
Zolpidem Tartrate	Zolpidem Tartrate	30	14
Cephalexin	Cephalexin	29	16
Fenofibrate	Fenofibrate Nanocrystallized	29	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	26	suppressed
Primidone	Primidone	26	suppressed
Spironolactone	Spironolactone	26	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	26	13
Doxazosin Mesylate	Doxazosin Mesylate	25	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	24	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	24	11
Breo Ellipta	Fluticasone/Vilanterol	23	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	23	15
Ezetimibe	Ezetimibe	23	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	23	suppressed
Benazepril Hcl	Benazepril Hcl	22	suppressed
Valacyclovir	Valacyclovir Hcl	22	suppressed
Estradiol	Estradiol	21	suppressed
Levofloxacin	Levofloxacin	21	15
Ondansetron Odt	Ondansetron	21	suppressed
Meloxicam	Meloxicam	20	suppressed
Novolog Flexpen	Insulin Aspart	20	suppressed
Pregabalin	Pregabalin	20	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	13
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	19	suppressed
Gemtesa	Vibegron	19	suppressed
Methylphenidate Er	Methylphenidate Hcl	19	suppressed
Nystatin	Nystatin	19	16
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	18	suppressed
Nitroglycerin	Nitroglycerin	18	13
Bupropion Hcl Sr	Bupropion Hcl	17	suppressed
Bethanechol Chloride	Bethanechol Chloride	16	suppressed
Eszopiclone	Eszopiclone	16	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	16	11
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	16	11
Oxybutynin Chloride	Oxybutynin Chloride	16	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	16	suppressed
Propranolol Hcl Er	Propranolol Hcl	16	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Bumetanide	Bumetanide	15	suppressed
Ipratropium Bromide	Ipratropium Bromide	15	suppressed
Januvia	Sitagliptin Phosphate	15	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Baclofen	Baclofen	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	14	suppressed
Nyamyc	Nystatin	14	suppressed
Potassium Citrate Er	Potassium Citrate	14	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	14	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	14	suppressed
Ventolin Hfa	Albuterol Sulfate	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Euthyrox	Levothyroxine Sodium	13	suppressed
Ibandronate Sodium	Ibandronate Sodium	13	suppressed
Morphine Sulfate Er	Morphine Sulfate	13	suppressed
Olanzapine	Olanzapine	13	suppressed
Qvar Redihaler	Beclomethasone Dipropionate	13	suppressed
Topiramate	Topiramate	13	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	12	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Valsartan	Valsartan	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Naproxen	Naproxen	11	suppressed
Silodosin	Silodosin	11	suppressed
Temazepam	Temazepam	11	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error